Jan 8 (Reuters) - InMed Pharmaceuticals Inc IN.TO :
* INMED ANNOUNCES RESULTS OF SECOND PHASE 1 CLINICAL TRIAL OF INM-755 CBN CREAM IN HEALTHY SUBJECTS
* INMED PHARMACEUTICALS INC - RESULTS OF STUDY 102 INDICATE THAT INM-755 CREAM WAS SAFE AND WELL-TOLERATED
* INMED PHARMACEUTICALS - REGULATORY APPLICATIONS FOR A PHASE 2 STUDY IN PATIENTS WITH EB ARE IN PREPARATION, PLANNED TO BE FILED IN H1 2021